Production of Chorionic Somatomammotropin (oCS), Fetal Growth and Growth of the Placenta and the Corpus Luteum in Ewes Treated with 2-Bromo-α-Ergocryptine*

Publisher Website
Google Scholar
Abstract
Ewes [40] treated with bromocryptine (2-bromo-.alpha.-ergocryptine) from midgestation onward were compared with 52 control ewes. RIA [radioimmunoassay] for PRL [prolactin] revealed that the treated ewes were severely hypoprolactinemic. No modification of the concentrations of chorionic somatomammotropin (oCS) in blood (as determined by radioreceptor assay) occurred with this treatment at any gestational stage; between 80-100 days of pregnancy, placental oCS concentrations increased 4-6 .times. [136 .+-. 6 .mu.g/g fresh tissue wt (n = 6), as compared with 22 .+-. 5 .mu.g/g fresh wt (n = 12), P < 0.001]. Maximal placental oCS levels occurred 1 mo. earlier (80-85 days) in the treated animals and were twice those of untreated animals (70 .+-. 5 .mu.g/g fresh wt, n = 13 at 110-120 days, P < 0.001). From 110-120 days of pregnancy onwards, placental oCS concentrations in treated animals dropped to control levels. Placental and fetal growth as well as oCS and PRL levels in fetal blood were not modified by maternal hypoprolactinemia. Up to 140 days of pregnancy, the gestational corpus luteal weight decreased by 14%, but this decrease was highly significant (703 .+-. 24 mg, n = 32 in the controls; 607 .+-. 18 mg, n = 38 in the treated ewes; P < 0.01), although it is known that both PRL and LH [luteinizing hormone] are necessary to maintain the cyclic corpus luteum in the ewe. oCS biosynthesis may depend on some kind of endocrine control; gestational corpora lutea may be maintained, at least in part, by a placental luteotrophic complex.